The Study to Test the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction (EMPACT-MI) trial screened 6610 participants with AMI and randomized 6522 to empagliflozin or placebo in addition to standard of care. The median (interquartile) age was 64 (56-71) years and 75.1% of patients were male. Major comorbidities included hypertension (69.1%), type 2 diabetes (31.7%), prior myocardial infarction (13.0%), and atrial fibrillation (10.9%). The majority (74.3%) of patients presented with an ST-elevation myocardial infarction. Overall, 56.9% of patients had acute signs or symptoms of congestion requiring treatment and 78.3% had left ventricular systolic dysfunction with ejection fraction <45%. Clinical characteristics, including baseline demographics, rates of revascularization, and cardiovascular medications at discharge were largely comparable to recent trials of the post-AMI population.
The EMPACT-MI trial will establish the benefit and risks of empagliflozin treatment in patients with AMI.
结果:测试Empagliflozin对急性心肌梗死患者心力衰竭住院和死亡率的影响的研究(EMPACT-MI)试验筛选了6610名AMI患者,并随机分配6522名接受依帕列净或安慰剂治疗。中位(四分位数)年龄为64(56-71)岁,75.1%的患者为男性。主要合并症包括高血压(69.1%),2型糖尿病(31.7%),既往心肌梗死(13.0%),房颤(10.9%)。大多数(74.3%)的患者出现ST段抬高型心肌梗死。总的来说,56.9%的患者有需要治疗的急性充血体征或症状,78.3%的患者有左心室收缩功能障碍,射血分数<45%。临床特征,包括基线人口统计,血运重建率,出院时的心血管药物在很大程度上与近期AMI后人群的试验相当.
结论:EMPACT-MI试验将确定empagliflozin治疗AMI患者的益处和风险。